U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C35H47N5O6
Molecular Weight 633.7776
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BI-44370

SMILES

CC1=CC(C[C@@H](OC(=O)N2CCC(CC2)N3CCC4=C(NC3=O)C=CC=C4)C(=O)N5CCC(CC5)N6CCOCC6)=CC(C)=C1O

InChI

InChIKey=HTLWMOKBJQKDIJ-WJOKGBTCSA-N
InChI=1S/C35H47N5O6/c1-24-21-26(22-25(2)32(24)41)23-31(33(42)38-12-8-28(9-13-38)37-17-19-45-20-18-37)46-35(44)39-14-10-29(11-15-39)40-16-7-27-5-3-4-6-30(27)36-34(40)43/h3-6,21-22,28-29,31,41H,7-20,23H2,1-2H3,(H,36,43)/t31-/m1/s1

HIDE SMILES / InChI
BI 44370 was developed as a calcitonin gene-related peptide receptor antagonist for the treatment of acute migraine attacks. In spite of the positive results from the phase II clinical trials, the BI-44370 study has been discontinued.

Approval Year

Sample Use Guides

BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity
Route of Administration: Oral
Name Type Language
BI-44370
Code English
BI44370
Code English
BI 44370 TA
Code English
J3.353.239C
Code English
BI-44370-BS
Code English
1-PIPERIDINECARBOXYLIC ACID, 4-(1,2,4,5-TETRAHYDRO-2-OXO-3H-1,3-BENZODIAZEPIN-3-YL)-, (1R)-1-((4-HYDROXY-3,5-DIMETHYLPHENYL)METHYL)-2-(4-(4-MORPHOLINYL)-1-PIPERIDINYL)-2-OXOETHYL ESTER
Systematic Name English
4-(2-OXO-1,2,4,5-TETRAHYDRO-3H-1,3-BENZODIAZEPINE-3-YL)PIPERIDINE-1-CARBOXYLIC ACID (R)-.ALPHA.-((4-MORPHOLINOPIPERIDINO)CARBONYL)-3,5-DIMETHYL-4-HYDROXYPHENETHYL ESTER
Systematic Name English
Code System Code Type Description
CAS
866086-05-7
Created by admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
PRIMARY
PUBCHEM
23654987
Created by admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
BI-44370
Created by admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
PRIMARY Official Title: A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe IntensityPurpose: The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared to placebo and an active comparator.
FDA UNII
7L3WOA232W
Created by admin on Sat Dec 16 11:18:58 GMT 2023 , Edited by admin on Sat Dec 16 11:18:58 GMT 2023
PRIMARY